Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 16/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12991241 | 0.95 | REN (0.53) | RENSMN1; SMN2ALDH1A1PKMHPGD | |
| Trifluoroacetic Acid SCHEMBL2900906 | 0.91 | REN (0.49) | REN | |
| Trifluoroacetic Acid SCHEMBL2900615 | 0.90 | REN (0.50) | RENSMN1; SMN2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL2902743 | 0.88 | REN (0.61) | RENSMN1; SMN2ALDH1A1HPGD | |
| Trifluoroacetic Acid SCHEMBL2894195 | 0.88 | REN (0.61) | RENSMN1; SMN2ALDH1A1HPGD | |
| Trifluoroacetic Acid SCHEMBL3515062 | 0.88 | REN (0.51) | REN | |
| Trifluoroacetic Acid SCHEMBL2901043 | 0.88 | REN (0.48) | REN | |
| SCHEMBL2902623 | 0.87 | REN (0.55) | RENSMN1; SMN2ALDH1A1 | |
| SCHEMBL12990654 | 0.85 | REN (0.53) | RENSMN1; SMN2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL2894272 | 0.85 | REN (0.49) | RENSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2202228-B1 | AMIDE COMPOUNDS AND USE OF THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-8329691-B2 | Amide compounds and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100324010-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-2202228-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2010-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324010-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | REN, ACE, AGT | REN 1/4885SMN1; SMN2 4704/4885ALDH1A1 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.